Condition: Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations · Sponsor: Taiho Oncology, Inc.
The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics (PK) of zipalertinib in participants with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) harboring EGFR ex20ins mutations and other mutations.
This description comes directly from the study's public registry record.
Taiho Oncology, INC · +1 844-878-2446 · medicalinformation@taihooncology.com
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham | Birmingham, Alabama, United States | Withdrawn |
| City of Hope - Duarte | Duarte, California, United States | Recruiting |
| Beth Israel Deaconess Medical Center | Boston, Massachusetts, United States | Recruiting |
| Comprehensive Cancer Centers of Nevada - Central Valley - Twain | Las Vegas, Nevada, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center - Basking Ridge | Basking Ridge, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center - Monmouth | Middletown, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center - Bergen | Montvale, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center - Commack | Commack, New York, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center - Westchester | Harrison, New York, United States | Recruiting |
| MSK Cancer Center | Long Island City, New York, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center - Nassau | Uniondale, New York, United States | Recruiting |
| Gabrail Cancer and Research Center | Canton, Ohio, United States | Recruiting |
+ 68 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05967689